glp 1 drugs and fatty liver Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Disease: A Systematic Review GLP-1 and Your Liver: What

Slowing gastric emptying: This slows down the rate at which food leaves the stomach, leading to reduced appetite and lower caloric intake

Systemic administration of anorexic gut peptide hormones impairs hedonic-driven sucrose consumption in mice

doi: 10.2337/db11-0979 36 SarsonDLWoodSMKansalPCBloomSR

Wegovy and Zepbound are now fully FDA approved for chronic weight management, regardless of diabetes status, as long as you meet the BMI or health condition criteria

The bio-availability of the DPP-4 inhibitors is very good and the pharmacodynamic- as well as the pharmacokinetic characteristics lead to the above mentioned clinically sufficient DPP-4 inhibition with once daily dosing (only vildagliptin has to be dosed twice daily) (18, 19)

Abbreviations ADA: American Diabetes Association CV: Cardiovascular CVOTs: Cardiovascular outcome trials GLP-1RA: Glucagon-like peptide-1 receptor agonists HR: Hazard ratios MACE: Major cardiovascular events SGLT-2i: Sodiumglucose transporter-2 inhibitors T2DM: Type 2 diabetes mellitus References Giugliano D, Maiorino MI, Longo M, Bellastella G, Chiodini P, Esposito K